Pharma Focus Asia

FINTEPLA[®] (fenfluramine) Oral Solution Approved in the EU

Thursday, February 09, 2023

UCB’s FINTEPLA® (fenfluramine) oral solution approved in the European Union (EU) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients two years of age and older.

LGS is a developmental and epileptic encephalopathy where seizures are frequent, inducing high level of trauma injuries which negatively impacts development and quality of life. Seizures are often resistant to currently available medications, making the approval especially important for the individuals affected and families.

Fenfluramine is now an important additional treatment option for those impacted by this difficult to treat condition in Europe. This approval improves treatment outcomes, by addressing the high unmet need for new treatments for people living with LGS and rare epilepsies.

Fenfluramine is a serotonin releasing agent, and stimulating multiple 5-HT receptor sub-types through the release of serotonin. Fenfluramine reduces seizures by acting as an agonist at specific serotonin receptors in the brain, including the 5-HT1D, 5-HT2A, and 5-HT2C receptors, and also by acting on the sigma-1 receptor. The precise mode of action of fenfluramine in Dravet syndrome and Lennox-Gastaut syndrome is not known.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024